Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

15.6%

5 terminated out of 32 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

13%

4 trials in Phase 3/4

Results Transparency

20%

2 of 10 completed with results

Key Signals

2 with results67% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (5)
P 1 (1)
P 2 (7)
P 3 (3)
P 4 (1)

Trial Status

Completed10
Unknown8
Recruiting5
Terminated5
Withdrawn2
Active Not Recruiting2

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT06476678RecruitingPrimary

Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions

NCT04075305Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

NCT05453760CompletedPrimary

Lung Ultrasound in the Early Detection of Postoperative Pulmonary Complications After Esophagectomy

NCT00431756Active Not Recruiting

Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus

NCT05406024CompletedPrimary

Feasibility Study CORPPS

NCT05176002Phase 1Active Not RecruitingPrimary

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

NCT02558504Phase 4CompletedPrimary

Radiofrequency in the Treatment of Barrett's Oesophagus

NCT04681248UnknownPrimary

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

NCT00288119Recruiting

Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

NCT06481449RecruitingPrimary

Definitive Radiotherapy for Cervical and Upper Thoracic Esophageal Cancer (ChC&UES): A Multi-center Real World Study

NCT05736705Not ApplicableWithdrawnPrimary

Monopolar and Bipolar in Esophageal ESD

NCT06348381RecruitingPrimary

Prediction of Anastomotic Complications and Recurrent Laryngeal Nerve Injury Based on Postoperative Early Endoscopic Evaluation

NCT03108885TerminatedPrimary

Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence

NCT00318903Phase 2Completed

Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer

NCT04489368UnknownPrimary

Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning

NCT03057288Not ApplicableCompletedPrimary

Prospective Study Evaluating the Feasibility of Fiducial Markers Placement for Patients With Esophageal or Rectal Cancer

NCT02395705Phase 3CompletedPrimary

Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma

NCT01802203Completed

trūFreeze® Spray Cryotherapy Patient Registry

NCT04481100Phase 2UnknownPrimary

CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer

NCT02601079Not ApplicableTerminatedPrimary

Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis

Scroll to load more

Research Network

Activity Timeline